The 13th International AIDS Society Conference on HIV Science (IAS 2025)

Kigali, Rwanda 13 July 2025 - 17 July 2025

Can pregnant, lactating people use lenacapavir to prevent HIV infection?

The use of lenacapavir is highly efficacious in pregnant and lactating people (PLP), with zero participants acquiring HIV, as shown by the results of the PURPOSE 1 study.

Can pregnant, lactating people use lenacapavir to prevent HIV infection?

17 hours ago

Personalized approach may improve PrEP uptake in MSM, transgenders

a day ago by

A recent study in the Philippines has identified key demographic and behavioural patterns among Filipino men who have sex with men (MSM) and transgender individuals (TGIs) regarding their awareness of pre-exposure prophylaxis (PrEP) and modality preferences.

Personalized approach may improve PrEP uptake in MSM, transgenders

a day ago

Ultrashort inpatient TB prevention feasible in advanced HIV, cryptococcal meningitis patients

13 Aug 2025 by

The IMPROVE trial shows the feasibility and safety of 1-month isoniazid and rifapentine (1HP) in an inpatient setting as tuberculosis preventive therapy (TPT) in patients with advanced HIV disease (AHD) and cryptococcal meningitis (CM).

Ultrashort inpatient TB prevention feasible in advanced HIV, cryptococcal meningitis patients

13 Aug 2025

F/TAF plus cobicistat-boosted PIs maintained virologic suppression in children with HIV

13 Aug 2025 by

Treatment with emtricitabine/tenofovir alafenamide (F/TAF) and cobicistat-boosted atazanavir (ATV/c) or darunavir (DRV/c) maintained high rates of virologic suppression through 48 weeks in children living with HIV, based on two cohorts of the GS-US-216-0128 study presented at IAS 2025.

F/TAF plus cobicistat-boosted PIs maintained virologic suppression in children with HIV

13 Aug 2025

Dual noninferior to triple ART in maintaining viral suppression among PLWH

12 Aug 2025 by

Switching to maintenance dual antiretroviral therapy (ART) with DTG+3TC* or ATV/r+3TC** was noninferior to continuing triple current ART with TDF+3TC+EFV*** or DTG+3TC+TDF⁺ in maintaining virologic suppression for up to 96 weeks among people living with HIV (PLWH), according to the MODERATO trial presented at IAS 2025.

Dual noninferior to triple ART in maintaining viral suppression among PLWH

12 Aug 2025

Lenacapavir serves its PURPOSE in young individuals

11 Aug 2025 by

Twice-yearly subcutaneous (SC) lenacapavir demonstrates high efficacy, favourable safety, and consistent pharmacokinetics (PK) as pre-exposure prophylaxis (PrEP) for HIV-negative youth (aged 16–25 years) in an analysis of the phase III PURPOSE 1 (P1) and PURPOSE 2 (P2) trials.

Lenacapavir serves its PURPOSE in young individuals

11 Aug 2025